NPCE (NeuroPace) Common Stock : $0.03 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NeuroPace Common Stock?

NeuroPace's quarterly common stock increased from Jun. 2024 ($0.03 Mil) to Sep. 2024 ($0.03 Mil) but then stayed the same from Sep. 2024 ($0.03 Mil) to Dec. 2024 ($0.03 Mil).

NeuroPace's annual common stock increased from Dec. 2022 ($0.03 Mil) to Dec. 2023 ($0.03 Mil) and increased from Dec. 2023 ($0.03 Mil) to Dec. 2024 ($0.03 Mil).

NeuroPace Common Stock Historical Data

The historical data trend for NeuroPace's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroPace Common Stock Chart

NeuroPace Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

0.02

0.03

NeuroPace Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															0.03	0.03	0.03	0.03	0.03

NeuroPace Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

NeuroPace Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

455 N. Bernardo Avenue, Mountain View, CA, USA, 94043

Website

https://www.neuropace.com

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Executives

Martha Morrell	officer: Chief Medical officer	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd.	10 percent owner	CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker	director, officer: Chief Executive Officer	ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger	director	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p.	10 percent owner	2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley	officer: General Counsel and Secretary	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade	director	6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield	director	C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer	director	9701 JERONIMO, IRVINE CA 92618
Evan Norton	director	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob	director	2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan	director	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet	director, officer: Chief Executive Officer	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043